BTAI
Price
$3.41
Change
+$0.09 (+2.71%)
Updated
Aug 7 closing price
Capitalization
20.65M
SYBX
Price
$1.36
Change
-$0.02 (-1.45%)
Updated
Aug 7 closing price
Capitalization
15.92M
Interact to see
Advertisement

BTAI vs SYBX

Header iconBTAI vs SYBX Comparison
Open Charts BTAI vs SYBXBanner chart's image
BioXcel Therapeutics
Price$3.41
Change+$0.09 (+2.71%)
Volume$14.77M
Capitalization20.65M
Synlogic
Price$1.36
Change-$0.02 (-1.45%)
Volume$3.22K
Capitalization15.92M
BTAI vs SYBX Comparison Chart in %
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BTAI vs. SYBX commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a StrongBuy and SYBX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (BTAI: $3.41 vs. SYBX: $1.36)
Brand notoriety: BTAI and SYBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 216% vs. SYBX: 6%
Market capitalization -- BTAI: $20.65M vs. SYBX: $15.92M
BTAI [@Biotechnology] is valued at $20.65M. SYBX’s [@Biotechnology] market capitalization is $15.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileSYBX’s FA Score has 1 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • SYBX’s FA Score: 1 green, 4 red.
According to our system of comparison, SYBX is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 6 TA indicator(s) are bullish while SYBX’s TA Score has 4 bullish TA indicator(s).

  • BTAI’s TA Score: 6 bullish, 4 bearish.
  • SYBX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BTAI is a better buy in the short-term than SYBX.

Price Growth

BTAI (@Biotechnology) experienced а +160.31% price change this week, while SYBX (@Biotechnology) price change was -11.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BTAI($20.7M) has a higher market cap than SYBX($15.9M). SYBX YTD gains are higher at: -2.793 vs. BTAI (-42.999). SYBX has higher annual earnings (EBITDA): -13.66M vs. BTAI (-24.24M). BTAI has more cash in the bank: 31M vs. SYBX (17.3M). SYBX has less debt than BTAI: SYBX (0) vs BTAI (106M). BTAI has higher revenues than SYBX: BTAI (1.85M) vs SYBX (0).
BTAISYBXBTAI / SYBX
Capitalization20.7M15.9M130%
EBITDA-24.24M-13.66M178%
Gain YTD-42.999-2.7931,540%
P/E RatioN/A6.19-
Revenue1.85M0-
Total Cash31M17.3M179%
Total Debt106M0-
FUNDAMENTALS RATINGS
BTAI vs SYBX: Fundamental Ratings
BTAI
SYBX
OUTLOOK RATING
1..100
9786
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10046
PRICE GROWTH RATING
1..100
3647
P/E GROWTH RATING
1..100
10029
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BTAI's Valuation (80) in the Biotechnology industry is in the same range as SYBX (86). This means that BTAI’s stock grew similarly to SYBX’s over the last 12 months.

BTAI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYBX (100). This means that BTAI’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's SMR Rating (46) in the Biotechnology industry is somewhat better than the same rating for BTAI (100). This means that SYBX’s stock grew somewhat faster than BTAI’s over the last 12 months.

BTAI's Price Growth Rating (36) in the Biotechnology industry is in the same range as SYBX (47). This means that BTAI’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's P/E Growth Rating (29) in the Biotechnology industry is significantly better than the same rating for BTAI (100). This means that SYBX’s stock grew significantly faster than BTAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAISYBX
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 22 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WD79.914.43
+5.87%
Walker & Dunlop
EONR0.290.01
+5.09%
EON Resources Inc
PHM120.670.44
+0.37%
Pultegroup
EVLV6.98-0.14
-1.97%
Evolv Technologies Holdings
ARBE1.28-0.09
-6.57%
Arbe Robotics Ltd